AI Article Synopsis
- The study aimed to determine the incidence of gingival overgrowth caused by amlodipine, which is not well understood.
- The research involved 115 dental patients who had taken amlodipine for over 3 months, diagnosing gingival overgrowth through clinical observations and checking for improvements after stopping the drug.
- Results showed that 3.4% of patients experienced gingival hyperplasia, particularly in the front teeth area, indicating a link between the severity of gingival inflammation and the dosage of the medication.
Article Abstract
Aims: Since the incidence of gingival overgrowth induced by amlodipine remains poorly defined, this study was carried out with an aim to determine the incidence.
Materials And Methods: Dental patients who received amlodipine (N = 115), for more than 3 months were studied to determine the drug-induced gingival overgrowth. Clinical diagnosis of drug-induced overgrowth was verified by disappearance or decreased severity of gingival overgrowth after withdrawal of the causative drug.
Results: The prevalence rate of amlodipine-induced gingival hyperplasia among experimental patients was 3.4%, while it was not observed among the control subjects. Oral examination revealed gingival overgrowth as a lobular or nodular enlargement on interdental papilla located in the anterior interproximal regions.
Conclusions: In this study, there was a significant relationship between gingival inflammation resulting from dental plaque and drug dosage, and hyperplasia.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033891 | PMC |
| http://dx.doi.org/10.4103/0972-124X.131332 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!